Targeted inhibitors of the key factors of the IL6 signaling pathway, including IL6 (such as siltuximab), IL6R (such as tocilizumab), GP130 (such as olamkicept), and STAT3 (such as danvatirsen), have been widely studied, and many drugs have been employed in clinical trials for treating some types of cancers [10]. Here, STAT3 is linked to cancer.